Regeneron brings first COVID-19 antibody 'cocktail' into human tests

Regeneron on Thursday began the first human trials of a medicine that's designed to treat, and possibly prevent, coronavirus infection.

The Tarrytown, New York-based biotech will test its treatment, a cocktail of two engineered antibodies, in two placebo-controlled studies of hospitalized and non-hospitalized COVID-19 patients.